Wang Haiyan, Zhao Fangfang, Cai Shanbao, Pu Youguang
Department of Clinical Geriatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, PR China.
Department of Laboratory Research Center, Anhui Provincial Cancer Hospital, West Branch of the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, PR China.
J Bone Oncol. 2019 May 11;17:100241. doi: 10.1016/j.jbo.2019.100241. eCollection 2019 Aug.
Chemoresistance prevents curative potential of chemotherapy in most cases. MicroRNAs (miRNAs) are key players in regulating chemoresistance in osteosarcoma, which is the most common primary bone cancer. Bisulfite sequencing and quantitative real time PCR analyses showed that miR-193a expression is downregulated by DNA hypermethylation at its promoter region in a chemoresistant cell line, SJSA-1, compared to a chemosensitive cell line G-292. Introduction of a miR-193a mimic in SJSA-1 cells or an antagomir into G-292 cells confirmed the role of miR-193a in osteosarcoma chemoresistance. Bioinformatics together with biochemical assays showed that insulin receptor substrate 2 (IRS2) is a target of miR-193a. Our data concludes that miR-193a plays a role in the osteosarcoma chemoresistance and thus might serve as a useful biomarker for osteosarcoma prognosis.
在大多数情况下,化疗耐药性会阻碍化疗的治愈潜力。微小RNA(miRNA)是调节骨肉瘤(最常见的原发性骨癌)化疗耐药性的关键因素。亚硫酸氢盐测序和定量实时PCR分析表明,与化疗敏感细胞系G-292相比,在化疗耐药细胞系SJSA-1中,miR-193a的表达因其启动子区域的DNA高甲基化而下调。在SJSA-1细胞中引入miR-193a模拟物或在G-292细胞中引入抗miR证实了miR-193a在骨肉瘤化疗耐药中的作用。生物信息学与生化分析表明,胰岛素受体底物2(IRS2)是miR-193a的一个靶标。我们的数据表明,miR-193a在骨肉瘤化疗耐药中起作用,因此可能作为骨肉瘤预后的有用生物标志物。